Non-Current Assets
Indefinite-Lived Research and Development Assets
Merck & Co. Indefinite-Lived Research and Development Assets increased by 35.0% to $4.13B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 35.0%, from $3.06B to $4.13B. Over 4 years (FY 2021 to FY 2025), Indefinite-Lived Research and Development Assets shows an upward trend with a 97.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ4 2021
Last reportedQ4 2025Feb 24, 2026
How to read this metric
Higher values indicate significant investment in future growth, but also carry higher risk of impairment if projects fail.
Detailed definition
The carrying value of acquired in-process research and development projects that are not yet amortized because their use...
Peer comparison
Highly specific to R&D-intensive industries like pharmaceuticals and biotechnology.
Metric ID:
indefinite_lived_rd_assetsHistorical Data
5 periods
| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $274M | $1.34B | $2.1B | $3.06B | $4.13B |
| QoQ Change | — | +389.4% | +56.5% | +45.9% | +35.0% |
| YoY Change | — | +389.4% | +56.5% | +45.9% | +35.0% |
Range$274M – $4.13B
CAGR>999%
Avg YoY Growth+131.7%
Median YoY Growth+51.2%
Current Streak4+ quarters growth
Indefinite-Lived Research and Development Assets at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s indefinite-lived research and development assets?
- Merck & Co. (MRK) reported indefinite-lived research and development assets of $4.13B in Q4 2025.
- How has Merck & Co.'s indefinite-lived research and development assets changed year-over-year?
- Merck & Co.'s indefinite-lived research and development assets increased by 35.0% year-over-year, from $3.06B to $4.13B.
- What is the long-term trend for Merck & Co.'s indefinite-lived research and development assets?
- Over 4 years (2021 to 2025), Merck & Co.'s indefinite-lived research and development assets has grown at a 97.1% compound annual growth rate (CAGR), from $274M to $4.13B.
- What does indefinite-lived research and development assets mean?
- The value of ongoing research projects that have not yet been launched as products.